Sanchez Larysa, Wang Yucai, Siegel David S, Wang Michael L
Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
J Hematol Oncol. 2016 Jun 30;9(1):51. doi: 10.1186/s13045-016-0283-0.
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.
达雷妥尤单抗是一种靶向CD38的人源单克隆抗体，CD38是一种在多发性骨髓瘤（MM）细胞上过度表达的细胞表面蛋白。临床前研究表明，达雷妥尤单抗通过多种机制诱导MM细胞死亡，包括补体依赖性细胞毒性（CDC）、抗体依赖性细胞介导的细胞毒性（ADCC）、抗体依赖性细胞吞噬作用（ADCP）和凋亡。鉴于达雷妥尤单抗在临床试验中显示出令人鼓舞的疗效和可接受的安全性，它已成为骨髓瘤的一种新型治疗选择，并成为美国食品药品监督管理局（FDA）批准用于治疗MM的首个单克隆抗体。
Zotero 插件